Abstract
This scoping review synthesizes existing research comparing traditional Chinese medicine (TCM) and contemporary treatments (CTs) for managing psoriasis vulgaris (PsV). A thorough literature search was conducted across multiple databases through February 2024, identifying relevant systematic reviews, randomized controlled trials (RCTs), quasi-experimental, and observational studies that contrast TCM approaches with CTs for PsV. From an initial pool, 195 articles were analyzed, indicating a growing interest in this comparative area, with most studies involving sample sizes between 30 and 100 participants. Key interventions included both internal and topical applications of Chinese herbal medicines, notably Rehmanniae Radix, Arnebiae Radix, and Smilacis Glabrae Rhizoma. Outcomes focused on PASI scores, quality of life metrics, and adverse effects. Results suggest that TCM offers efficacy in improving PASI scores and quality of life; however, evidence concerning toxicity profiles, recurrence rates, and comorbidity outcomes remains sparse. Notable research gaps include a lack of comprehensive data on newer treatment modalities, particularly biologics. Future studies should aim to delineate subjects and interventions in greater detail to support clinical applicability.